Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“The Alzheimer’s Plan”: CFS/ME Patients Seek “Loosening” Of Approval Requirements

Executive Summary

FDA’s recent guidance on drug development in early-stage Alzheimer’s did not change the standard of evidence required for approval, agency official says amid calls to ease requirements for chronic fatigue syndrome/myalgic encephalomyelitis.

You may also be interested in...



Chronic Fatigue Meeting Shows Benefits, Hurdles To Patient-Focused Drug Development

The two-day workshop on chronic fatigue syndrome/myalgic encephalomyelitis elicited extensive, detailed testimony from patients about their symptoms and current treatment that will inform FDA policy, but it also underscored the challenges of explaining FDA’s regulatory processes to the patient community.

Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says

A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.

Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel